Search
Inotersen
go.drugbank.com/drugs/DB14713ApprovedInvestigationalIt was FDA approved in October 2018. … Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults.
Categories: Antisense Elements (Genetics)Asunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Categories: Antivirals for treatment of HCV infections, P-glycoprotein inhibitorsProducts: SUNVEPRA® 100MG CÁPSULAS BLANDASAnthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalIt is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue … Anthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax.
Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnIt is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
Synonyms: 4-BENZYL-2-(A-NAPHTYL)-1,2,4-THIADIAZOLIDINE-3,5-DIONE, 4-Benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dioneCategories: Heterocyclic Compounds, 1-Ring, Glycogen Synthase Kinase 3, antagonists & inhibitorsFosdenopterin
go.drugbank.com/drugs/DB16628Approved[L43075] In September 2022, the EMA approved the use of fosdenopterin.[L43372,L43433] … Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase
Categories: MATE 1 Substrates, MATE 2 InhibitorsSynonyms: C(PMP)Cenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalIt received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. … Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli.
Vutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249010] TTR mutations lead to the formation of misfolded TTR proteins, which form amyloid fibrils that deposit in different types of tissues. … [L42065] This siRNA therapeutic is indicated for the treatment of neuropathies associated with hereditary transthyretin-mediated amyloidosis (ATTR), a condition caused by mutations in the TTR gene.
Categories: Antisense Elements (Genetics)Treosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigational[L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575] … Treosulfan is a prodrug alternative to [busulfan] for myeloablative conditioning prior to hematopoietic stem cell transplantation.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: L-threitol-1,4-dimethanesulfonateTrioxsalen
go.drugbank.com/drugs/DB04571ApprovedWithdrawnIt is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema. … In research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.[3] The compound is has been explored for development of antisense oligonucleotides that can be
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: 6-hydroxy-β,2,7-trimethyl-5-benzofuranacrylic acid, δ-lactone, 2',4,8-TrimethylpsoralenManitimus
go.drugbank.com/drugs/DB06481InvestigationalFK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in kidney transplant patients, potentially offering a breakthrough in immunosuppressive therapy.
Synonyms: (2Z)-2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHYL)PHENYL)HEPT-2-EN-6-YNAMIDE, (2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamideCategories: Heterocyclic Compounds, 1-Ring